Increased risk of essential tremor in migraine: A population-based retrospective cohort study

Chi-Ieong Lau1,2,3,4, Che-Chen Lin5,6, Hsuan-Ju Chen5,7, Han-Cheng Wang1,8,9, Wei-Hung Chen1,8, Ji-An Liang10,11*

1 Department of Neurology, Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan, 2 Division of Clinical Neurology, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, United Kingdom, 3 Institute of Cognitive Neuroscience, University College London, Queen Square, London, United Kingdom, 4 College of Medicine, Fu-Jen Catholic University, Taipei, Taiwan, 5 Management Office for Health Data, China Medical University Hospital, Taichung, Taiwan, 6 Healthcare Service Research Center (HSRC), Taichung Veterans General Hospital, Taichung, Taiwan, 7 College of Medicine, China Medical University, Taichung, Taiwan, 8 College of Medicine, Taipei Medical University, Taipei, Taiwan, 9 College of Medicine, National Taiwan University, Taipei, Taiwan, 10 Graduate Institute of Clinical Medical Science, School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan, 11 Department of Radiation Oncology, China Medical University Hospital, Taichung, Taiwan

* d4615@mail.cmuho.org.tw

Abstract

Purpose
To examine the long-term risk of essential tremor (ET) in migraine.

Methods
Using population-based administrative data from a subset of the National Health Insurance Research Database (NHIRD) of Taiwan, we identified 22,696 newly diagnosed migraineurs (mean age 44.5 years) and a matched migraine-free cohort of 90,784 individuals in the period 2000–2008. Multivariable Cox proportional hazards regression analysis was conducted for assessing the ET risk for the migraine cohort compared to the migraine-free cohort.

Results
After adjusting for covariates, the migraine cohort had a 1.83-fold increased risk (95% CI 1.50–2.23) of subsequent ET in comparison to the migraine-free cohort (8.97 vs. 4.81 per 10,000 person-years). In the subgroup analysis, patients with migraine were associated with higher risks of ET, regardless of gender, age or the existence of comorbidities.

Conclusion
Our findings demonstrated an association between migraine and ET, suggesting a possible shared pathophysiology underpinning both disorders.
Introduction

Both migraine and essential tremor (ET) are common neurological disorders. Over the past two decades, there has been controversy regarding the possible link between the two disorders [1–6]. In an early cross-sectional study, Biary et al. disclosed a bi-directional association between migraine and ET, with more than one-third of ET patients coexisted with migraine and almost one-fifth of migraineurs had ET [1]. Another study also showed the co-segregation of classical migraine in one-fourth of patients with hereditary essential tremor [2]. Together both studies suggest comorbidity between migraine and ET, yet a common criticism argued that they suffered from suboptimal comparisons with uncontrolled patient features such as age and sex [6]. More recently, however, two age- and sex-matched case-control studies reported conflicting results [4, 5]. A Chinese study disclosed a higher prevalence of lifetime migraine (22%) among 150 patients with ET compared with 150 controls (12.7%) [5]. By contrast, Barbanti et al. revealed no significant difference in the frequency of lifetime migraine between 110 patients with ET and 110 matched controls [4]. Hu et al. concluded that the contradictory results might be due to the different ethnic background of the studied populations as well as the differences in patient characteristics [5].

To date, there has been little agreement on the potential link between migraine and ET, with no large population-based studies existing in the literature. Exploring their relationship may shed light on the incompletely understood pathophysiology of both disorders as well as their possible shared mechanism. To this end, we conducted a nation-wide population-based cohort study from the NHIRD of Taiwan, to address the question of whether migraine is associated with subsequent ET.

Methods

Data source

The National Health Research Institutes (NHRI) built the NHIRD which involved the reimbursement claims data from the National Health Insurance (NHI) program of Taiwan. The Taiwan NHI was established by the Government and performed as a single-payer and compulsory health insurance that covers 99% of the 23 million population in Taiwan. The Longitudinal Health Insurance Database (LHID) is a subset of the NHRID constructed from one million randomly sampled insured individuals. According to the NHRI, there was no significant difference between the LHID and the NHIRD in respect to age and sex distribution. The LHID consists of annual claims data including the beneficiary registries, prescriptions as well as all outpatient and inpatient records. Disease records are based on the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM). All data and related metadata were deposited in an appropriate public repository in the National Health Research Institutes (NHRI). The data on the study population that were obtained from the NHIRD (http://nhird.nhri.org.tw/en/index.html) are maintained in the NHIRD (http://nhird.nhri.org.tw/). The NHRI is a nonprofit foundation established by the government. Only citizens of the Republic of China who fulfill the requirements of conducting research projects are eligible to apply for the NHIRD. The use of NHIRD is limited to research purposes only. Applicants must follow the Computer-Processed Personal Data Protection Law (http://www.winklerpartners.com/?p=987) and related regulations of National Health Insurance Administration and NHRI, and an agreement must be signed by the applicant and his/her supervisor upon application submission. All applications are reviewed for approval of data release.
**Ethics statement**

Before releasing the LHID for the purpose of research, the NHRI eliminated the original identification information and encrypted an anonymous number for each individual in order to ensure privacy. The NHIRD encrypts patient personal information to protect privacy and provides researchers with anonymous identification numbers associated with relevant claims information, including sex, date of birth, medical services received, and prescriptions. Therefore, patient consent is not required to access the NHIRD. This study was approved to fulfill the condition for exemption by the Institutional Review Board (IRB) of China Medical University (CMUH104-REC2-115-CR1). The IRB also specifically waived the consent requirement.

**Study population**

We conducted a population-based cohort study designed to explore the association between ET and migraine. The migraine cohort consisted of all newly diagnosed migraine patients aged ≥ 20 years old (ICD-9-CM 346) from January 1, 2000 to December 31, 2008. The initial diagnosis date was assigned as the index date of the migraine cohort. We identified the migraine-free cohort by propensity score (PS) matching [7]. Logistic regression model was used to estimate the probability of migraine assignment by calculating the PS. We incorporated age, sex, hypertension, diabetes mellitus (DM), coronary artery disease (CAD), stroke, epilepsy, head injury, restless leg syndrome (RLS), depression, dementia, asthma, chronic obstructive pulmonary disease (COPD), and year of index date in the logistic regression model. For each migraine case, the 4-fold corresponding migraine-free controls were selected from the nearest propensity score by greedy algorithm. We excluded the individuals with the history of ET diagnosis (ICD-9-CM 333.1) before the index date as well as individuals with Parkinson’s disease (ICD-9-CM 332) before the end of follow-up. Each individual was observed in both cohorts beginning at the index date until a diagnosis of ET (ICD-9-CM 333.1) was made, a subject being withdrawn from the Taiwan NHI or the end of the follow-up (December 31, 2011).

We considered the following comorbidities as the confounding factors of the current study. A comorbidity of an individual is defined as having the comorbidity before the index date. These included hypertension (ICD-9-CM 401–405), DM (ICD-9-CM 250), CAD (ICD-9-CM 410–414), stroke (ICD-9-CM 430–438), epilepsy (ICD-9-CM 345), head injury (ICD-9-CM 310.2, 800, 801, 803, 804, 850–854, and 959.01), RLS (ICD-9-CM 333.90, and 333.99), depression (ICD-9-CM 296.2–296.3, 300.4 and 311), dementia (ICD-9-CM 290, 294.1 and 331.0), asthma (ICD-9-CM 493), and COPD (ICD-9-CM 491, 492, and 496). In addition, migraine prophylaxis used by the individuals during the period of follow-up (including amitriptyline, clomipramine, duloxetine, flunarizine, fluoxetine, gabapentin, imipramine, paroxetine, sertraline, topiramate, valproate, venlafaxine and beta blockers) were also considered as confounding factors.

**Statistical analysis**

Data were expressed as frequencies and percentages for categorical data and as means and standard deviations for continuous variables. We compared the distributions of age, sex, and comorbidity between the migraine cohort and the migraine-free cohort. A value of 0.1 standardized mean difference or less indicates a negligible difference in means between two cohorts by using standardized mean difference [8]. We calculated the incidence density of ET for each study cohort and measured the cumulative incidence curves by using the Kaplan-Meier method. To test the incidence curve difference between the migraine and the migraine-free cohorts, we applied the log-rank test. To compare the risk for developing ET between the
migraine and the migraine-free cohorts, we used single variable and multi-variable Cox proportional hazard models to estimate the crude and adjusted hazard ratios (HRs) and the corresponding 95% confidence intervals (CIs). We also performed a subgroup analysis between the migraine and the migraine-free cohorts as stratified by age, sex, and comorbidities. We applied SAS 9.4 software (SAS Institute, Cary, NC, USA) for data management and used R software (R Foundation for Statistical computing, Vienna, Austria) for statistical analysis and incidence curve calculation. We set the p-value at less than 0.05 as the significant level for two-side testing.

Results
This study involved a total of 22,696 migraine subjects and a 4-fold migraine-free cohort (N = 90,784) (Table 1). The mean age of the study population was 44.5 years and the majority of cases were female (72%). There were no significant differences between the migraine cohort and migraine-free cohort in the distributions of age, sex, and comorbidities. The migraine cohort had a higher proportion of use of migraine prophylaxis than the migraine-free cohort.

Table 2 shows the incidences and HRs of ET between the migraine and the migraine-free cohorts. A total of 152 and 319 ET events occurred in the migraine and the migraine-free cohorts respectively. The incidences of subsequent ET were 8.97 and 4.81 per 10000 person-years in the migraine and the migraine-free cohorts respectively.

Fig 1 demonstrates a significantly higher cumulative incidence for ET in the migraine cohort than the migraine-free cohort (log-rank test p < 0.0001). After adjusting for age, sex, comorbidities and migraine prophylaxis, the individuals with migraine were associated with a
Table 2. Incidence of subsequent essential tremor and multivariate Cox proportional hazards regression analysis measured hazard ratio for the study cohort.

| Variable               | Event | PYs      | Rate | Crude HR (95% CI) | Adjusted HR (95% CI) |
|------------------------|-------|----------|------|-------------------|----------------------|
| **Migraine**           |       |          |      |                   |                      |
| No                     | 319   | 662554   | 4.81 | ref               | ref                  |
| Yes                    | 152   | 169531   | 8.97 | 1.85 (1.53–2.24)  | 1.83 (1.50–2.23)     |
| **Age group**          |       |          |      |                   |                      |
| 20–44                  | 120   | 480277   | 2.50 | ref               | ref                  |
| 45–64                  | 200   | 259087   | 7.72 | 3.09 (2.46–3.88)  | 2.49 (1.95–3.19)     |
| >65                    | 151   | 92721    | 16.3 | 6.50 (5.11–8.26)  | 4.35 (3.21–5.90)     |
| **Sex**                |       |          |      |                   |                      |
| Female                 | 357   | 613662   | 5.82 | ref               | ref                  |
| Male                   | 114   | 218423   | 5.22 | 0.90 (0.73–1.11)  | 0.83 (0.67–1.03)     |
| **Hypertension**       |       |          |      |                   |                      |
| No                     | 247   | 632119   | 3.91 | ref               | ref                  |
| Yes                    | 224   | 199966   | 11.2 | 2.86 (2.39–3.43)  | 1.08 (0.85–1.36)     |
| **DM**                 |       |          |      |                   |                      |
| No                     | 402   | 780050   | 5.15 | ref               | ref                  |
| Yes                    | 69    | 52035    | 11.3 | 2.56 (1.98–3.30)  | 1.21 (0.92–1.58)     |
| **CAD**                |       |          |      |                   |                      |
| No                     | 308   | 711943   | 4.33 | ref               | ref                  |
| Yes                    | 163   | 120142   | 12.4 | 3.12 (2.58–3.78)  | 1.32 (1.05–1.67)     |
| **Stroke**             |       |          |      |                   |                      |
| No                     | 457   | 819200   | 5.58 | ref               | ref                  |
| Yes                    | 14    | 12885    | 10.9 | 1.92 (1.13–3.28)  | 0.58 (0.33–1.00)     |
| **Epilepsy**           |       |          |      |                   |                      |
| No                     | 455   | 825066   | 5.51 | ref               | ref                  |
| Yes                    | 16    | 7018     | 22.8 | 4.10 (2.49–6.74)  | 3.06 (1.84–5.11)     |
| **Head injury**        |       |          |      |                   |                      |
| No                     | 427   | 781991   | 5.46 | ref               | ref                  |
| Yes                    | 44    | 50094    | 8.78 | 1.59 (1.17–2.17)  | 1.30 (0.95–1.77)     |
| **RLS**                |       |          |      |                   |                      |
| No                     | 470   | 831351   | 5.65 | ref               | ref                  |
| Yes                    | 1     | 734      | 13.6 | 2.39 (0.34–16.9)  | 1.32 (0.19–9.41)     |
| **Depression**         |       |          |      |                   |                      |
| No                     | 385   | 769697   | 5.00 | ref               | ref                  |
| Yes                    | 86    | 62387    | 13.8 | 2.73 (2.16–3.46)  | 1.92 (1.51–2.45)     |
| **Dementia**           |       |          |      |                   |                      |
| No                     | 463   | 829336   | 5.58 | ref               | ref                  |
| Yes                    | 8     | 2749     | 29.1 | 5.12 (2.55–10.3)  | 1.32 (0.64–2.72)     |
| **Asthma**             |       |          |      |                   |                      |
| No                     | 414   | 769389   | 5.38 | ref               | ref                  |
| Yes                    | 57    | 62696    | 9.09 | 1.67 (1.27–2.21)  | 0.82 (0.61–1.11)     |
| **COPD**               |       |          |      |                   |                      |
| No                     | 353   | 745556   | 4.73 | ref               | ref                  |
| Yes                    | 118   | 86528    | 13.6 | 2.86 (2.32–3.53)  | 1.53 (1.21–1.94)     |
| **Migraine prophylaxis** |   |          |      |                   |                      |
| No                     | 142   | 407776   | 3.48 | ref               | ref                  |

(Continued)
1.83-fold higher risk of ET compared to the migraine-free individuals (HR = 1.83, 95% CI = 1.50–2.23). The risk of developing ET appears to increase with age. Individuals aged 45–64 and more than 65 had adjusted HRs of 2.49 (95% CI = 1.95–3.19) and 4.35 (95% CI = 3.21–5.90) compared with individuals aged 20–44. In additional, the results also demonstrated trends showing increasing risks of ET in subjects with CAD (HR = 1.32, 95% CI = 1.05–1.67), epilepsy (HR = 3.06, 95% CI = 1.84–5.11), depression (HR = 1.92, 95% CI = 1.51–2.45), and COPD (HR = 1.53, 95% CI = 1.21–1.94).

Table 2. (Continued)

| Variable | Event | PYs  | Rate | Crude HR (95% CI) | Adjusted HR (95% CI) |
|----------|-------|------|------|------------------|----------------------|
| Yes      | 329   | 424309 | 7.75 | 2.24 (1.84–2.73) | 1.10 (0.88–1.37)     |

Model adjusted for age (categorical), sex, hypertension, DM, CAD, stroke, epilepsy, head injury, RLS, depression, dementia, asthma, COPD and migraine prophylaxis

PYs: person-years; rate: incidence rate, per 10000 person-years; DM: diabetes mellitus; CAD: coronary arterial disease; RLS: restless leg syndrome; COPD, chronic obstructive pulmonary disease

https://doi.org/10.1371/journal.pone.0173586.t002

Fig 1. Cumulative incidence of subsequent essential tremor in the comparison and migraine cohorts.
Table 3 shows the risks of ET in different tiers of frequency of annual medical visits due to migraine. After adjustment for age, sex, comorbidities and migraine prophylaxis, the HRs of subsequent ET were 1.57 (95% CI = 1.27–1.95), 5.42 (95% CI = 2.96–9.95) and 30.9 (95% CI = 18.3–52.2) for the migraineurs with < 6 times, 6–11 times and ≥ 12 times of annual visits respectively, in comparison to the individuals without migraine. Thus, there is a trend showing increasing risk of ET with increasing frequency of medical visits due to migraine (p for trend < 0.0001).

Table 4 demonstrates the risks of ET in the migraine cohort compared with the migraine-free cohort as stratified by age, sex, and comorbidities. Comparing with the migraine-free cohort, the HRs of ET were 1.92 (95% CI = 1.52–2.41) and 1.71 (95% CI = 1.14–2.56) for female and male migraineurs respectively. Comparing with the migraine-free cohort, the HRs of ET were 2.08

### Table 3. Incidence of subsequent essential tremor and multivariate Cox proportional hazards regression analysis measured hazard ratio by various tiers of frequency of annual medical visits related to migraine.

| Average annual medical visits related to migraine | N   | Event | PYs     | Rate   | Adjusted HR (95% CI) |
|-------------------------------------------------|-----|-------|---------|--------|----------------------|
| Migraine-free cohort                            | 90784 | 319   | 662554  | 4.81   | ref                  |
| Migraine cohort                                 |     |       |         |        |                      |
| <6                                              | 21967 | 126   | 165489  | 7.61   | 1.57 (1.27–1.95)     |
| 6–11                                            | 531   | 11    | 3120    | 35.3   | 5.42 (2.96–9.95)     |
| ≥12                                             | 198   | 15    | 922     | 163    | 30.9 (18.3–52.2)     |
| p for trend                                     | <0.0001 |      |         |        |                      |

Model adjusted for age (continuous), sex, hypertension, DM, CAD, stroke, epilepsy, head injury, RLS, depression, dementia, asthma, COPD and migraine prophylaxis

PYs: person-years; rate: incidence rate, per 10000 person-years

https://doi.org/10.1371/journal.pone.0173586.t003

### Table 4. Incidence of subsequent essential tremor and multivariate Cox proportional hazards regression analysis measured hazard ratio for the study cohort stratified by age, sex, and comorbidities.

| Variable   | Migraine-free cohort | Migraine cohort | Adjusted HR (95% CI) |
|------------|----------------------|-----------------|----------------------|
| Age group<sup>a</sup> | Event | PYs | Rate | Event | PYs | Rate |                     |
| 20–44      | 76       | 385313 | 1.97 | 44     | 94964 | 4.63 | 1.95 (1.32–2.89)     |
| 45–64      | 127      | 201103 | 6.32 | 73     | 57985 | 12.6 | 1.92 (1.43–2.58)     |
| ≥65        | 116      | 76138  | 15.2 | 35     | 16582 | 21.1 | 1.53 (1.04–2.26)     |
| Sex<sup>b</sup> | Female | 243   | 489931 | 4.96 | 114 | 123731 | 9.21 | 1.92 (1.52–2.41)     |
|            | Male | 76 | 172622 | 4.40 | 38  | 45801 | 8.30 | 1.71 (1.14–2.56)     |
| Comorbidity<sup>c</sup> | No      | 84   | 400716 | 2.10 | 44  | 88534 | 4.97 | 2.08 (1.41–3.05)     |
|            | Yes | 235 | 261838 | 8.98 | 108 | 80997 | 13.3 | 1.66 (1.31–2.09)     |

<sup>a</sup>Model adjusted for sex, hypertension, DM, CAD, stroke, epilepsy, head injury, RLS, depression, dementia, asthma, COPD, and migraine prophylaxis

<sup>b</sup>Model adjusted for age (continuous), hypertension, DM, CAD, stroke, epilepsy, head injury, RLS, depression, dementia, asthma, COPD and migraine prophylaxis

<sup>c</sup>Model adjusted for age (continuous), sex and migraine prophylaxis

PYs: person-years; rate: incidence rate, per 10000 person-years

https://doi.org/10.1371/journal.pone.0173586.t004
(95% CI = 1.31–2.09) for the migraine patients without any comorbidity and with at least one comorbidity respectively.

**Discussion**

In the present study, we found that patients with migraine were associated with a 1.83-fold increased risk of future ET, after adjusting for age, sex, comorbidities and migraine prophylaxis. In addition, the risk appeared to be highest in the youngest group, i.e. age between 20 to 44 years, with an adjusted HR of 1.93. More frequent migraine-related health-care-seeking behaviour was associated with higher incidence of ET.

Except for the study of Barbanti et al. [4], our finding is in accordance with the results of previous studies that support a link between migraine and ET (Table 5). As mentioned, the early cross-sectional studies were limited by the lack of control in sex and age [1, 2], whereas the latter case-control studies done in tertiary-referral centers may not reflect the condition in the general population [4, 5]. Notably, unlike the majority of previous studies (except Biary, Koller et al.[1]) that showed unidirectional association between both disorders by examining the lifetime prevalence of migraine in ET, the current study, however, investigated the occurrence of ET in migraine over the span of a decade. Comparing to previous studies, this is by far the largest and the only population-based study to demonstrate an association between migraine and ET.

The mean age of our cohorts (at index date), i.e. 45 years, is younger than that of previous studies. Further analysis showed increased risks of ET among migraine cases across all age groups (i.e. <45, 45–64 and ≥65 years) compared to the migraine-free cohort. Notably, there seems to be an even stronger association, an adjusted HR of 1.95, in the youngest age group 20–44 years and a less prominent correlation in the oldest group (≥65 years), i.e. an adjusted HR of 1.53. The reason underlying this is obscure but could be due to the different age distribution of the two disorders.

Migraine is the most common neurological disorder, affecting approximately 15–20% of the general population [9, 10]. ET is estimated to have a prevalence of 0.3–4% in individuals ≥40 years old, with higher incidence of up to 14% in the elderly population [11]. ET was originally considered to be a “benign” monosymptomatic tremorogenic disorder (4-12Hz) with substantial hereditary basis [11]. Emerging evidence suggests that ET may have subtle
neurological deficits beyond its hallmark of kinetic tremor [12]. These include cerebellar dysfunction, bradykinesia, disturbed ocular movements as well as non-motor features, namely voice disorders [13], upper airway dysfunction [14], impairment visual reaction time [15], mild cognitive deficits, impaired executive functions and neuropsychiatric symptoms [11, 12]. Neuroimaging studies have shown widespread alterations in the cerebello-thalamo-cortical circuit [16, 17], with cerebellar involvement as the most consistent finding [18]. Intriguingly, the cerebellum and brainstem circuits have also been implicated in the pathophysiology of migraine [19, 20]. Migraineurs, notably those with aura (MA), showed subclinical hypermetria and other cerebellar signs, suggestive of abnormal functioning of the lateral cerebellum [21]. Indeed, both MA and migraineurs without aura (MwA) showed increased prevalence of silent posterior circulation infarctions, with a majority of lesions located at the cerebellum [22]. The risk appeared to be strongest in cases with MA, female gender as well as higher attack frequency. As such, although the link between migraine and ET remains speculative, it might be possible that the increased risk of ET in migraine is mainly driven by MA, possibly via a shared pathophysiology that implicates the same cerebellar circuits. This notion was partially elucidated by a study showing no subtle alternation in physiological tremors of migraineurs compared to controls, regardless of the number of years experiencing migraine, suggesting that the possible link between migraine and ET might be the result of an acute event of the olivo-cerebellar circuit rather than a progressive alternation of tremorgenic mechanisms [3]. These speculations, however, should be interpreted with caution and require future pathological and imaging studies to provide definitive evidence.

Our findings demonstrated a staggeringlly increased incidence of ET in migraineurs seeking more frequently for migraine-related health care. This cohort of subjects often consists of MA and chronic migraineurs who want to be reassured of the benign nature of their headaches as well as requesting for migraine prophylaxis. Both MA and chronic migraine are known to activate several extrapyramidal nuclei such as the red nucleus and substantia nigra during migraine attacks [23]. One plausible speculation is that repeated migraineurs attacks may lead to dysfunction or structural changes of these nuclei that may give rise to movement disorders. Intriguingly, a recent epidemiological study supported the notion that MA are more prone to develop Parkinson’s disease [24], a possible comorbidity of ET [25].

Arguably, our findings are based on a population mainly composed of the Han ethnic group and thus may not be applied to Caucasian due to the genetic differences, as demonstrated by the conflicting results between the Chinese [5] and Italian [4] studies. On the other hand, migraine and ET may share a common genetic background. For instance, a functional variant (Ser9Gly) of the dopamine D3 receptor (DRD3), although not confirmed in other studies [26], is associated with risk and age-at-onset of ET, the frequencies of the functional variant were found to be similar between ET patients with and without migraine [27]. Nevertheless, there is a scarcity of pathophysiological evidence to support the association between the two disorders. Future research should be undertaken to elucidate the potential common pathophysiology of migraine and ET.

**Strength of the current study**

The major strength of the present study is that we analysed a large, national dataset containing a representative cohort of 1 000 000 citizens covered by the NHI of Taiwan. The large sample size and the long (10 years) observation period offered significant power for statistical analyses. In addition, we robustly controlled the confounding effects of migraine prophylaxis that would lead to misdiagnosis of ET because of their potential side effects of tremor. These commonly used medications included anticonvulsants (valproate acid, topiramate and gabapentin...
Selective serotonin re-uptake inhibitors (SSRIs) (fluoxetine, sertraline, paroxetine), serotonin norepinephrine reuptake inhibitors (SNRI) (venlafaxine, duloxetine) (Morgan and Sethi 2005) [29] [30], tricyclic antidepressant (amitriptyline, clomipramine and imipramine) [31], calcium channel blocker (flunarizine) [32] and beta blockers [33]. To the best of our knowledge, this has not been done in previous studies.

Limitations of the current study

First, we were unable to delineate between migraineurs with aura (MA) and migraineurs without aura because those two were not separately recorded in the NHIRD. As mentioned, the link between migraine and ET may be driven mainly by MA. Similarly, other factors such as family history, symptoms and severities of ET were impossible to be examined. Another concern is the accuracy of migraine and ET diagnoses. Nonetheless, the accuracy of the diagnoses might have been improved by the wide use of the ICHD-2 diagnostic criteria for migraine in Taiwan. The validity of the diagnoses was also improved by the routine verification of coding by the NHI Bureau of Taiwan for the eligibility of health insurance reimbursement. Third, another potential bias is that migraineurs with higher frequencies of seeking medical care for migraine would have had better chances in diagnosing with ET. Likewise, a longer follow-up might facilitate the diagnosis of ET in migraine patients under neurological surveillance. Last but not least, the NHIRD is used for health insurance claims and may not serve directly for scientific purposes. Future studies are warranted to replicate our findings.

Conclusion

Our nationwide population-based cohort study showed that migraine increases the likelihood of incident ET. This provides additional evidence to support the link between migraine and ET and may suggest the presence of shared pathophysiology, whereby increasing the vulnerability of developing one condition with another. Yet much remains unexplained, future genetic, pathological imaging and epidemiological studies are warranted to explore the underpinning networks that potentially link these two common but complex neurological disorders.

Supporting information

S1 STROBE Checklist. Checklist of items that should be included in reports of observational studies.

(DOC)

Acknowledgments

This study is supported in part by Taiwan Ministry of Health and Welfare Clinical Trial and Research Center of Excellence (MOHW105-TDU-B-212-133019), China Medical University Hospital, Academia Sinica Taiwan Biobank Stroke Biosignature Project (BM10501010037), NRPB Stroke Clinical Trial Consortium (MOST 105-2325-B-039-003), Tseng-Lien Lin Foundation, Taichung, Taiwan, Taiwan Brain Disease Foundation, Taipei, Taiwan, and Katsuzo and Kiyo Aoshima Memorial Funds, Japan; and CMU under the Aim for Top University Plan of the Ministry of Education, Taiwan. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. No additional external funding received for this study.
**Author Contributions**

**Conceptualization:** C-IL, J-AL.

**Data curation:** C-IL, C-CL, H-JC, H-CW, W-HC, J-AL.

**Formal analysis:** C-IL, C-CL, H-JC, H-CW, W-HC, J-AL.

**Funding acquisition:** J-AL.

**Investigation:** C-IL, J-AL.

**Methodology:** C-IL, J-AL.

**Project administration:** J-AL.

**Resources:** C-IL, J-AL.

**Software:** C-CL, H-JC, J-AL.

**Supervision:** J-AL.

**Validation:** C-IL, C-CL, H-JC, H-CW, W-HC, J-AL.

**Visualization:** C-IL, C-CL, H-JC, H-CW, W-HC, J-AL.

**Writing – original draft:** C-IL, C-CL, H-JC, H-CW, W-HC, J-AL.

**Writing – review & editing:** C-IL, C-CL, H-JC, H-CW, W-HC, J-AL.

**References**

1. Biary N, Koller W, Langenberg P. Correlation between essential tremor and migraine headache. J Neurol Neurosurg Psychiatry. 1990; 53:1060–2. PMID: 2292698

2. Bain PG, Findley LJ, Thompson PD, Gresty MA, Rothwell JC, Harding AE, et al. A study of hereditary essential tremor. Brain. 1994; 117:805–24. PMID: 7922467

3. Duval C, Norton L. Tremor in patients with migraine. Headache. 2006; 46:1005–10. https://doi.org/10.1111/j.1526-4610.2006.00471.x PMID: 16732847

4. Barbanti P, Fabbrini G, Aurilia C, Defazio G, Colosimo C, Berardelli A. No association between essential tremor and migraine: a case-control study. Cephalalgia. 2010; 30:686–9. https://doi.org/10.1177/0333102409352253 PMID: 20511207

5. Hu Y, Tang W, Liu R, Dong Z, Chen X, Pan M, et al. Higher prevalence of migraine in essential tremor: a case-control study. Cephalalgia. 2014; 34:1142–9. https://doi.org/10.1177/0333102414531153 PMID: 24728302

6. Kuiper M, Hendriks S, Koehler PJ. Headache and Tremor: Co-occurrences and Possible Associations. Tremor Other Hyperkinet Mov (N Y). 2015; 5:285.

7. Stürmer T, Wyss R, Glynn RJ, Brookhart MA. Propensity scores for confounder adjustment when assessing the effects of medical interventions using nonexperimental study designs. J Intern Med. 2014; 275:570–80. https://doi.org/10.1111/joim.12197 PMID: 24520806

8. Mamdani M, Sykora K, Li P, Normand SL, Steiner DL, Austin PC, et al. Reader’s guide to critical appraisal of cohort studies: 2. Assessing potential for confounding. BMJ 2005; 330:960–2. https://doi.org/10.1136/bmj.330.7497.960 PMID: 15845982

9. Jensen R, Stovner LJ. Epidemiology and comorbidity of headache, Lancet Neurol. 2008; 7:354–61. https://doi.org/10.1016/S1474-4422(08)70062-0 PMID: 18339350

10. Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF et al. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007; 68:343–9. https://doi.org/10.1212/01.wnl.0000252808.97649.21 PMID: 17261680

11. Bermejo-Pareja F. Essential tremor—a neurodegenerative disorder associated with cognitive defects? Nat Rev Neurol. 2011; 7:273–82. https://doi.org/10.1038/nrneurol.2011.44 PMID: 21467422

12. Louis ED. Non-motor symptoms in essential tremor: A review of the current data and state of the field. Parkinsonism Relat Disord. 2016; 22 Suppl 1:S115–8.
13. Gamboa J, Jiménez-Jiménez FJ, Nieto A, Cobeta I, Vegas A, Ortí-Pareja M, et al. Acoustic voice analysis in patients with essential tremor. J Voice. 1998; 12(4):444–52. PMID: 9988031

14. Jiménez-Jiménez FJ, Izquierdo-Alonso JL, Cabrera-Valdivia F, Mansilla-Lesmes M, Martínez-Martín P, Serrano-Iglesias JA. Dysfunction of the upper respiratory airways in patients with essential tremor. Presse Medica. 1995; 24(25):1152–1156.

15. Jiménez-Jiménez FJ, Rubio L, Alonso-Navarro H, Calleja M, Pilo-de-la-Fuente B, Plaza-Nieto JF, et al. Impairment of rapid repetitive finger movements and visual reaction time in patients with essential tremor. Eur J Neurol. 2010; 17(1):152–9. https://doi.org/10.1111/j.1468-1331.2009.02784.x PMID: 19765055

16. Deuschl G, Elble RJ. The pathophysiology of essential tremor. Neurology. 2000; 54:S14–20. PMID: 10854347

17. Tröster AI, Woods SP, Fields JA, Lyons KE, Pahwa R, Higginson CI, et al. Neuropsychological deficits in essential tremor: an expression of cerebello-thalamo-cortical pathophysiology? Eur J Neurol. 2002; 9:143–51. PMID: 11882055

18. Louis ED. Essential tremor: from bedside to bench and back to bedside. Curr Opin Neurol. 2014; 27:461–7. https://doi.org/10.1097/WCO.0000000000000115 PMID: 24950011

19. Barbanti P, Fabbrini G. Migraine and the extrapyramidal system. Cephalalgia. 2002; 22:2–11. https://doi.org/10.1080/03331024.2002.00313.x PMID: 11993609

20. Akerman S, Holland PR, Goadsby PJ. Diencephalic and brainstem mechanisms in migraine. Nat Rev Neurosci. 2011; 12:570–84. https://doi.org/10.1038/nrn3057 PMID: 21931334

21. Sándor PS, Mascia A, Seidel L, de Pasqua V, Schoenen J. Subclinical cerebellar impairment in the common types of migraine: a three-dimensional analysis of reaching movements. Ann Neurol. 2001; 49:668–72. PMID: 11357959

22. Kruit MC, van Buchem MA, Launer LJ, Terwindt GM, Ferrari MD. Migraine is associated with an increased risk of deep white matter lesions, subclinical posterior circulation infarcts and brain iron accumulation: the population-based MRI CAMERA study. Cephalalgia. 2010; 30:129–36. https://doi.org/10.1111/j.1468-2982.2009.01904.x PMID: 19515125

23. Welch KM, Cao Y, Aurora S, Wiggins G, Vikingstad EM. MRI of the occipital cortex, red nucleus, and substantia nigra during visual aura of migraine. Neurology. 1998; 51:1465–9. PMID: 9818884

24. Scher AI, Ross GW, Sigurdsson S, Garcia M, Gudmundsson LS, Sveinbjörnsson S, et al. Midlife migraine and late-life Parkinson's disease: AGES-Reykjavik study. Neurology. 2014; 83:1246–52. https://doi.org/10.1212/WNL.0000000000000840 PMID: 25230997

25. Fekete R, Jankovic J. Revisiting the relationship between essential tremor and Parkinson's disease. Mov Disord. 2011; 26:391–8. https://doi.org/10.1002/mds.23512 PMID: 21462256

26. Jiménez-Jiménez FJ, Alonso-Navarro H, García-Martín E, Lorenzo-Betancor O, Pastor P, Agúndez JA. Update on genetics of essential tremor. Acta Neurol Scand. 2013; 128(6):359–71. https://doi.org/10.1111/ane.12148 PMID: 23682623

27. Janneteau F, Junalot B, Jankovic J, Deng H, Lárge J, Lucotte G, et al. A functional variant of the dopamine D3 receptor is associated with risk and age-at-onset of essential tremor. Proc Natl Acad Sci U S A. 2006; 103:10753–8. https://doi.org/10.1073/pnas.0508189103 PMID: 16809426

28. Mulleners WM, McCrory DC, Linde M. Antiepileptics in migraine prophylaxis: an updated Cochrane review. Cephalalgia. 2015 Jan; 35(1):51–62. https://doi.org/10.1177/0333102414534325 PMID: 25115844

29. Fendt B, Weinmann H. Pharmacological prevention of migraine. BMJ. 2011; 342:d583. https://doi.org/10.1136/bmj.d583 PMID: 21335405

30. Morgan JC, Sethi KD. Drug-induced tremors. Lancet Neurol. 2005; 4(12):866–876 https://doi.org/10.1016/S1474-4422(05)70250-7 PMID: 16297844

31. Raethjen J, Lemke M R, Lindemann M, Wenzelburger R, Krack P, Deuschl G. 2001. Amitriptyline enhances the central component of physiological tremor. Journal of neurology, neurosurgery, and psychiatry. 2001; 70(1):79–82. https://doi.org/10.1136/jnnp.70.1.79 PMID: 11118252

32. Capella D, Laporte JF, Castel JM, Tristan C, Cas A, Morales-Oliva FJ: Parkinsonism, tremor, and depression induced by cinnarizine and flunarizine. BMJ. 1988; 297:722–723. PMID: 3147743

33. Silberstein SD. Treatment recommendations for migraine. Nature Reviews Neurology. 2008; 4:482–489.